Efficacy of pentoxifylline combined with edaravone and dexborneol in the treatment of patients with cerebral infarction

Zhang Xiaona; Gao Tao; Wang Yajie

doi:10.3969/j.issn.1672-8157.2025.05.006

Abstract：Objective To explore the clinical efficacy of pentoxifylline combined with edaravone and dexborneol in the treat-ment of acute cerebral infarction(ACI)and its effects on the levels of serum homocysteine(Hcy)and lipoprotein-associated phos-pholipase A2(Lp-PLA2).Methods A total of 82 patients with ACI admitted to the First Affiliated Hospital of Henan University of Science&Technology from August 2022 to October 2024 were selected and randomly divided into two groups using the standard random number table method.Both groups received standardized intravenous thrombolysis therapy.41 patients in the control group were treated with edaravone and dexborneol alone,while 41 patients in the observation group were treated with the combination of pentoxifylline and edaravone and dexborneol.Both groups were treated for 2 weeks.The therapeutic effects of the two groups were compared,and the levels of serum Hcy and Lp-PLA2 of the two groups of patients before and after treatment were measured.Results The total effective rate of the observation group was 92.68%(38/41),which was higher than that of the control group(75.61%(38/41))(χ2=4.479,P=0.034).After treatment,the score of the National Institutes of Health Stroke Scale(NIHSS)in the observation group((5.75±1.60)points)was lower than that in the control group((8.12±1.88)points)(t=6.147,P<0.05),and the score of the Activities of Daily Living Scale(ADL)in the observation group((83.35±8.92)points)was higher than that in the control group((69.08±8.42)points)(t=-7.449,P<0.05).After treatment,the peak velocity(Vp)and mean flow velocity(Vm)of the middle cerebral arteries on both sides in the observation group((71.58±1.72)cm·s-1,(18.65±1.99)cm·s-1)were higher than those of the control group((64.24±1.93)cm·s-1,(14.13±1.38)cm·s-1)(t=-18.180,-11.951,both P<0.05).After treatment,the levels of Hcy and Lp-PLA2 in the observation group((22.58±2.16)cm·s-1,(41.07±7.08)μg·L-1)were lower than those in the control group((28.72±2.08)cm·s-1,(55.65±6.92)μg·L-1)(t=13.111,9.430,both P<0.05).The incidence of adverse reactions in the control group was 12.20%(5/41),and the observation group was 17.07%(7/41),and there was no statistically significant difference between the two groups(χ2=0.390,P>0.05).Conclusion The combination of pentoxifylline and edaravone and dexborneol in the treatment of patients with ACI has definite clinical efficacy,which can promote the recovery of neurological function and improve the ability of daily living of patients,down-regulate the levels of serum Hcy and Lp-PLA2,and has good safety.